NextCure Inc., a clinical-stage biopharmaceutical company, announced it has entered into agreements with institutional and accredited investors for a private placement of approximately 2.5 million shares of common stock or pre-funded warrants at $8.52 per share, raising around $21.5 million. The offering, conducted under Section 4(a)(2) of the Securities Act and Regulation D, is not registered under federal or state securities laws. H.C. Wainwright & Co. acted as the exclusive placement agent. NextCure plans to use the net proceeds for general working capital and to extend its cash runway into the first half of 2027, supporting continued development of its two antibody drug conjugate programs.